S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Aclaris Therapeutics Stock Forecast, Price & News

-0.06 (-0.55%)
(As of 01/14/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
465,934 shs
Average Volume
443,030 shs
Market Capitalization
$661.90 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aclaris Therapeutics logo

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$6.48 million
Book Value
$0.88 per share


Net Income
$-51.01 million
Net Margins
Pretax Margin




Free Float
Market Cap
$661.90 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.97 out of 5 stars

Medical Sector

667th out of 1,405 stocks

Pharmaceutical Preparations Industry

324th out of 678 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

Is Aclaris Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics
or view top-rated stocks.

How has Aclaris Therapeutics' stock price been impacted by Coronavirus?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACRS shares have increased by 919.8% and is now trading at $10.81.
View which stocks have been most impacted by COVID-19

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Aclaris Therapeutics

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. The biotechnology company had revenue of $1.66 million for the quarter, compared to analysts' expectations of $1.82 million. Aclaris Therapeutics had a negative net margin of 1,187.63% and a negative trailing twelve-month return on equity of 54.41%.
View Aclaris Therapeutics' earnings history

What price target have analysts set for ACRS?

4 Wall Street analysts have issued 1-year target prices for Aclaris Therapeutics' stock. Their forecasts range from $26.00 to $50.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 233.0% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $10.81.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $661.90 million and generates $6.48 million in revenue each year. The biotechnology company earns $-51.01 million in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 59 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at (484) 324-7933, via email at [email protected], or via fax at 484-320-2344.

This page was last updated on 1/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.